Questions
Ipamorelin, answered directly.
Twenty-two real questions, each answered in a few cited sentences — no throat-clearing.
What does CJC-1295 and ipamorelin do?
Together they raise growth hormone through two receptors at once: CJC-1295 drives the GHRH pathway while ipamorelin fires a selective ghrelin-receptor pulse. A 2026 orthopaedic narrative review found the pair improved maximal muscle tetanic tension in a glucocorticoid-induced muscle-loss mouse model, but stressed the evidence is limited to animal studies [17]. The combination has no controlled human outcome trial.
How much CJC-1295 ipamorelin should I take?
There is no evidence-based dose. No controlled human trial has performed dose-finding for the combination, so any specific figure online is community convention, not a studied amount [13][17]. Ipamorelin's only human doses were given by IV in research settings [2][3], and this site does not provide a self-administration dose, volume, or schedule for the stack.
Does CJC-1295 ipamorelin work?
The mechanism raises growth hormone in the short term, and class-level human data support GHRP + GHRH synergy [8][13]. But no controlled human outcome trial of this specific combination has proven a wellness benefit. A 2024 review found a muscle-tension effect in mice while noting the evidence is animal-only [17]; a 2026 review flagged the absence of rigorous human trials and the potential for serious harm [18].
Where to inject CJC-1295 ipamorelin?
Community protocols use subcutaneous injection, but these regimens have no peer-reviewed human basis and this site gives no administration instruction. The only human ipamorelin doses on record were intravenous, in a hospital research setting [2][3]. Subcutaneous self-injection — the dominant real-world route — has never been characterized for safety or pharmacokinetics in humans.
Can you take CJC-1295 ipamorelin and sermorelin together?
There is no controlled trial of that three-way combination, so its safety and effect are uncharacterized. Mechanistically, sermorelin and CJC-1295 are both GHRH analogs — adding both would be largely redundant on the same receptor, while ipamorelin supplies the separate ghrelin-receptor pulse. This site does not recommend any combination; the class-level synergy data involve only paired GHRP + GHRH studies [7][8].
Can you take tesamorelin and ipamorelin together?
No controlled trial has tested tesamorelin plus ipamorelin. Tesamorelin is an FDA-approved GHRH analog; ipamorelin is an unapproved ghrelin-receptor peptide [3]. Mechanistically they hit different receptors, so the pairing parallels the CJC-1295 stack, but no human study supports it and this site gives no dosing guidance for it. The class synergy evidence comes from other GHRP + GHRH pairs [8][9].
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a) to release a growth-hormone pulse. Its 1998 founding study showed potent growth-hormone release (swine ED50 2.3 nmol/kg) with no rise in cortisol — the first selective growth-hormone secretagogue [1]. It is not an approved drug [3].
What does ipamorelin do for you?
In studies, ipamorelin triggers a discrete pulse of growth hormone by acting on the ghrelin receptor, without raising cortisol or prolactin [1]. Preclinically it increased rat bone growth dose-dependently [4] and reduced chemotherapy-related weight loss in ferrets [5]. In humans, its only efficacy trial — for postoperative ileus — failed [3]. Community-reported effects (sleep, recovery) are anecdotal.
What is ipamorelin peptide?
It is a five-amino-acid chain (a pentapeptide) engineered for protease resistance and receptor selectivity. Derived from GHRP-1, its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and it acts as a selective GHS-R1a (ghrelin receptor) agonist [1]. "Peptide" simply means a short protein-like chain; ipamorelin is among the most selective growth-hormone-secretagogue peptides characterized.
What are the risks of ipamorelin?
The documented risks center on uncharacterized long-term safety: no Phase 3 trial, no long-term human database, and a class-level cardiotoxicity signal — a 28-day rat study of a related ghrelin-receptor agonist found dose-dependent myocardial degeneration [6]. Theoretical concerns include IGF-1-related tumor promotion and impaired glucose control [16]. The one human trial showed no specific safety signal in a 7-day window [3].
Does ipamorelin reduce belly fat?
There is no human evidence that ipamorelin reduces belly fat. In a 2024 ferret study, intraperitoneal ipamorelin reduced cisplatin-induced weight loss by about 24% — a weight-protective effect, not fat loss [5]. In mice, it actually increased adiposity and leptin through a GH-independent mechanism [14]. Community reports of a leaner look over weeks are anecdotal and confounded by diet and training.
What are the downsides of ipamorelin?
The central downside is that the human evidence is thin and partly negative: the only efficacy trial failed [3], and no long-term safety data exist. Community-reported downsides include post-injection flushing, tingling, water retention, increased hunger, and a fading response after a few months — all anecdotal. The class-level cardiac signal [6] and GH-axis cautions are the documented concerns.
Why is ipamorelin being discontinued?
Ipamorelin was never a marketed drug to discontinue — its clinical development stopped after the Phase 2 ileus trial missed its primary endpoint (25.3 vs 32.6 hours, p=0.15) [3]. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list and reviewed it at the October 2024 PCAC meeting, restricting compounding-pharmacy access.
Does ipamorelin increase IGF-1?
Not reliably in short studies. In the dose-dependent rat bone-growth study, ipamorelin raised bone growth with no measurable change in total IGF-1 [4], suggesting early effects are driven by the growth-hormone pulse itself rather than sustained IGF-1 elevation. Class-level data show that chronic GHRP + GHRH co-administration can sustain IGF-1 [7], but ipamorelin monotherapy does not consistently do so.
How does CJC-1295 ipamorelin work?
The two peptides hit growth hormone through different receptors: CJC-1295 activates the GHRH receptor (cAMP pathway) for a sustained drive, while ipamorelin activates the ghrelin receptor (GHS-R1a, calcium pathway) for a discrete pulse [1]. Because the pathways are distinct, their effects can stack rather than overlap — the published rationale for the pairing [13]. The synergy is documented at the class level [8].
How to reconstitute CJC-1295 ipamorelin 5mg?
As a general handling note: ipamorelin is supplied as a lyophilized (freeze-dried) powder and reconstituted with bacteriostatic water for research handling, then kept refrigerated because peptides degrade with heat and freeze-thaw. This is a storage observation, not a dosing instruction — this site provides no milligram-to-milliliter math, injection volume, or preparation guidance for human use.
How long does ipamorelin stay in your system?
Ipamorelin's terminal half-life in healthy human volunteers is approximately 2 hours after IV dosing, with the growth-hormone pulse peaking around 40 minutes [2]. With a ~2-hour half-life, the peptide itself clears within several hours. The downstream growth-hormone pulse it triggers is brief and discrete rather than sustained [2].
Does ipamorelin make you hungry?
It can, because it acts on the ghrelin (hunger) receptor. Acute central ghrelin-receptor activation induced feeding in rats — a class-level appetite effect [15]. Community reports describe a hunger bump after injecting, generally milder than with GHRP-6 but still present for some. The selectivity that spares cortisol does not remove the appetite signal, which runs through the same receptor.
Will I gain weight on ipamorelin?
There is no human data to answer this directly. In mice, ipamorelin increased body weight, fat-pad weight, and leptin through a GH-independent mechanism [14]. In a ferret cachexia model it protected against weight loss [5]. Community reports vary. Any weight change would be confounded by appetite effects [15], diet, and training; no controlled human study has measured it.
Does ipamorelin increase appetite?
Mechanistically, yes — it is a ghrelin-receptor agonist, and ghrelin is the body's hunger hormone; class-level studies show central ghrelin-receptor activation induces feeding [15]. Reported appetite increase is described as milder than with GHRP-6 but real for some users (anecdotal). Mouse data also show GH-independent increases in adiposity and leptin alongside the appetite mechanism [14].
What does ipamorelin peptide do?
It selectively triggers a growth-hormone pulse by activating the ghrelin receptor, without the cortisol or prolactin spillover of older peptides [1]. In animals it increased bone growth [4] and protected against chemotherapy weight loss [5]; in its one human efficacy trial it failed [3]. It is studied as the pulsatile half of growth-hormone peptide stacks [13].
How long does it take for ipamorelin to work?
Pharmacologically, fast: the growth-hormone pulse peaks about 40 minutes after dosing in humans [2]. For the subjective effects people chase — sleep, recovery — community reports describe onset within one to two weeks, but these are anecdotal and unverified, with no controlled human trial measuring an onset time for any wellness outcome.